Obesity

A retrospective cohort study found that patients on GLP-1 agonists had a lower risk of periprosthetic joint infection but a higher risk of periprosthetic fractures following total knee arthroplasty.

At the American Association of Clinical Endocrinology 2025 Annual Meeting, Daniel Drucker, OC, MD, FRCPC, FRSC, FRS, discussed the evolving scope of GLP-1–based therapies, highlighting emerging molecules,...

A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...

Excess visceral fat, rather than BMI alone, is a key driver of cardiovascular risk in people with HIV receiving antiretroviral therapy. The study authors presented their findings at the Conference on...

In a presentation at the Practical Updates in Primary Care 2025 virtual conference, Angela Fitch, MD, FACP, MFOMA, Dipl ABOM, detailed the role primary care physicians play in obesity care and provided an...

At the Practical Updates in Primary Care 2025 conference, Julianne Blythe, MPA, PA-C, RPSGT, outlined practical strategies for identifying and managing obstructive sleep apnea, emphasizing screening tools,...

A study presented at the American College of Cardiology's 74th Annual Scientific Session found that GLP-1RA use in patients with psoriasis was linked to a lower incidence of major adverse cardiovascular...

A new study reveals that most patients discontinue GLP-1 receptor agonists within a year, with significantly higher dropout rates among those using them for weight loss rather than diabetes management. ...

The FDA has approved tirzepatide, the first-ever drug option to treat moderate to severe obstructive sleep apnea in adults with obesity.

In a recent randomized, double-blind, placebo-controlled study, researchers found reductions in both body weight and knee pain in individuals with obesity and knee osteoarthritis following weekly treatment...